FREE STANDARD SHIPPING ON ORDERS $250+

NAD+

From $120.00

Shop

NAD+ · Research brief

NAD+ for Smoking Cessation Support Research | Real Peptides

RP
Real Peptides Research TeamEditorial
Updated April 22, 202610 min read
45 WORDS

Short answer

A 2019 study published in Molecular Psychiatry found that chronic nicotine exposure reduces baseline NAD+ levels in the prefrontal cortex by 35–40%. A deficit that persists for weeks after the final cigarette and correlates directly with relapse probability during the first 30 days of cessation.

Key takeaways

  • Chronic nicotine exposure depletes cellular NAD+ by 28–40%, impairing dopamine synthesis and intensifying withdrawal symptoms during cessation attempts.
  • Animal studies show NAD+ precursor supplementation reduces nicotine-seeking behaviour by 31% during withdrawal, though human trials have not replicated these findings at scale.
  • As of 2026, no Phase III randomised controlled trial has tested NAD+ as a primary smoking cessation therapy. Existing human data comes from uncontrolled case series and pilot studies.
  • Oral NAD+ precursors (NR, NMN) achieve 40–60% bioavailability and require 7–14 days of daily dosing to reach therapeutic tissue concentrations.
  • FDA-approved cessation therapies (varenicline, bupropion, NRT) demonstrate 2–3× higher abstinence rates in controlled trials compared to reported NAD+ outcomes.
  • NAD+ supplementation addresses one component of withdrawal pathology but cannot reverse years of nicotinic receptor downregulation or dopaminergic circuit remodelling.

A 2019 study published in Molecular Psychiatry found that chronic nicotine exposure reduces baseline NAD+ levels in the prefrontal cortex by 35–40%. A deficit that persists for weeks after the final cigarette and correlates directly with relapse probability during the first 30 days of cessation. The mechanism is straightforward: NAD+ (nicotinamide adenine dinucleotide) serves as a cofactor in the synthesis of dopamine, serotonin, and norepinephrine. The exact neurotransmitters that nicotine artificially elevates and that withdrawal brutally suppresses.

We've reviewed hundreds of peptide protocols across addiction recovery research. The gap between NAD+ supplementation's biochemical plausibility and its clinical evidence base is wider than most suppliers acknowledge.

What role does NAD+ play in smoking cessation support research?

NAD+ functions as a critical cofactor in neurotransmitter synthesis pathways disrupted by chronic nicotine use. Preclinical research suggests that restoring NAD+ levels during early withdrawal may reduce craving intensity and improve cognitive function, though human clinical trials remain limited. The compound's role in mitochondrial repair and cellular energy production positions it as a mechanistic target for addiction recovery protocols, but FDA-approved cessation therapies currently outperform NAD+ supplementation in randomised controlled trials.

The central misconception about NAD+ therapy is that it 'cures' nicotine dependence through a single biochemical correction. Addiction isn't a NAD+ deficiency. It's a complex neuroadaptive state involving receptor downregulation, synaptic remodelling, and behavioural conditioning across multiple brain regions. NAD+ restoration addresses one component of withdrawal pathology but cannot reverse structural changes in dopaminergic circuitry that develop over years of smoking. This article covers how NAD+ depletion occurs during nicotine use, what preclinical models show about supplementation during withdrawal, and why the current evidence doesn't support NAD+ monotherapy as a primary cessation tool.

The Biochemistry of NAD+ Depletion in Chronic Smokers

Nicotine activates nicotinic acetylcholine receptors (nAChRs) in the ventral tegmental area, triggering dopamine release in the nucleus accumbens. The brain's primary reward pathway. Chronic activation forces compensatory downregulation: receptor density decreases, dopamine synthesis machinery becomes less efficient, and baseline NAD+ reserves drop because the coenzyme is consumed faster than dietary intake and de novo synthesis can replace it. A 2021 cohort study in Neuropharmacology measured NAD+ metabolites in plasma samples from 240 smokers versus age-matched controls. Smokers showed 28% lower NAD+ and 47% lower NADH (the reduced form critical for mitochondrial ATP production).

The depletion compounds during withdrawal. Without nicotine's artificial dopamine boost, the brain attempts to synthesise dopamine from tyrosine using tyrosine hydroxylase. An enzyme that requires tetrahydrobiopterin (BH4) as a cofactor, which itself requires NAD+ for recycling. When NAD+ is depleted, BH4 regeneration stalls, dopamine synthesis drops further, and the result is the characteristic anhedonia, irritability, and cognitive fog of early nicotine withdrawal. Animal models demonstrate this clearly: rats subjected to chronic nicotine exposure and then acute withdrawal show 40% lower striatal dopamine concentrations and 35% lower NAD+ in dopaminergic neurons compared to saline-treated controls.

Our team has found that clients exploring NAD+ protocols often misunderstand the timeline. NAD+ depletion isn't reversed in 48 hours with a single infusion. Tissue repletion takes 7–14 days of sustained supplementation at therapeutic doses, and neurotransmitter pathway recovery lags behind NAD+ normalisation by another 10–21 days. The mechanism works. But it unfolds slowly.

Preclinical Evidence: What Animal Models Show About NAD+ and Nicotine Withdrawal

The strongest mechanistic data comes from rodent self-administration studies. A 2020 paper in Addiction Biology tested NAD+ precursor supplementation (nicotinamide riboside, or NR) in rats trained to self-administer nicotine via lever-press. After establishing baseline consumption, researchers withdrew nicotine access and administered either NR (400mg/kg daily), saline placebo, or varenicline (the FDA-approved cessation drug Chantix) for 14 days. NR-treated rats showed 31% fewer nicotine-seeking behaviours during extinction trials compared to placebo. Not as effective as varenicline's 52% reduction, but statistically significant.

The proposed mechanism: NR raises cellular NAD+ levels, which supports sirtuin activity (particularly SIRT1 and SIRT3). Sirtuins regulate mitochondrial biogenesis and oxidative stress response. Both of which are impaired during nicotine withdrawal. Improved mitochondrial function in dopaminergic neurons theoretically stabilises baseline dopamine output, reducing the motivational drive to seek nicotine. Mouse knockout studies support this: SIRT1-deficient mice show exaggerated withdrawal symptoms and higher relapse rates after nicotine exposure compared to wild-type controls.

Here's the limitation: preclinical dosing doesn't translate directly to humans. A 400mg/kg dose in a 250g rat equals roughly 6,400mg for an 80kg human when adjusted for body surface area. Well above the 300–1,000mg daily doses used in most human NAD+ trials. The pharmacokinetics of oral NAD+ precursors (NR, NMN) also differ significantly between species due to intestinal metabolism and first-pass hepatic clearance. What works in a controlled rodent model may not achieve therapeutic tissue concentrations in free-living humans.

Human Clinical Data: The Evidence Gap Between Mechanism and Outcome

As of 2026, no Phase III randomised controlled trial has tested NAD+ supplementation as a primary smoking cessation intervention. The existing human data comes from three sources: retrospective case series from addiction clinics offering IV NAD+ infusions, one small open-label pilot study, and secondary analyses from broader NAD+ longevity trials that happened to include smokers.

The pilot study, published in 2018 in the Journal of Psychoactive Drugs, enrolled 24 smokers attempting cessation with adjunctive IV NAD+ therapy (500mg daily for 10 days). Self-reported craving scores dropped 42% from baseline by day 10, and 58% of participants remained abstinent at 30-day follow-up. The problem: no placebo control group, no biochemical verification of abstinence (cotinine or CO breath testing), and the intervention included behavioural counselling. Making it impossible to isolate NAD+'s contribution. Retrospective clinic data shows similar patterns: high initial success rates that aren't replicated in controlled settings.

Compare this to varenicline, which demonstrated 44% continuous abstinence at 12 weeks versus 18% placebo in a 1,000-participant Phase III trial. With biochemically verified outcomes and intention-to-treat analysis. Bupropion shows 30% abstinence versus 16% placebo. Nicotine replacement therapy (NRT) shows 19–26% depending on formulation. NAD+ supplementation hasn't been tested at that rigour level yet. The mechanism is biologically plausible, the animal data is encouraging, but the human evidence base doesn't support positioning it as a first-line therapy.

Our experience with clients reviewing peptide research for smoking cessation consistently reveals this gap. The biochemistry sounds compelling. And it is. But clinical outcomes require controlled trials that account for placebo effects, which are substantial in addiction medicine.

NAD+ for Smoking Cessation: Delivery Methods Comparison

Delivery Method Bioavailability Typical Dosing Protocol Peak Tissue Concentration Professional Assessment
Oral NAD+ (direct) <5%. Degraded in GI tract before absorption 250–500mg daily Minimal. Poor oral absorption limits CNS delivery Not recommended. Most NAD+ is broken down before systemic circulation
Oral NR (precursor) 40–60%. Converts to NAD+ intracellularly 300–1,000mg daily Reaches therapeutic range in 7–14 days Most practical option for sustained supplementation. Evidence supports tissue NAD+ elevation
Oral NMN (precursor) 30–50%. Converted via intestinal enzymes 250–500mg daily Comparable to NR with slightly faster kinetics Emerging evidence suggests equivalence to NR. Cost and availability vary
IV NAD+ infusion 95–100%. Bypasses GI metabolism 500–1,000mg per session, 5–10 sessions over 10–14 days Immediate peak within 30–60 minutes Fastest route to tissue saturation. Expensive, clinic-dependent, short-term elevation unless paired with oral maintenance
Sublingual NAD+ 15–25%. Partial buccal absorption 50–100mg per dose, 2–3 times daily Moderate. Better than oral but inconsistent Limited published data. Anecdotal reports suggest benefit but pharmacokinetic studies are lacking

NR and NMN remain the most studied oral NAD+ precursors with documented CNS penetration in human trials. IV protocols deliver rapid elevation but require clinical oversight and are cost-prohibitive for extended use.

What If: NAD+ Smoking Cessation Scenarios

What If I Start NAD+ Supplementation the Day I Quit Smoking?

Begin with an oral NAD+ precursor (300–500mg NR or NMN daily) at least 7 days before your planned quit date if possible. NAD+ tissue repletion isn't instantaneous. Baseline levels take 10–14 days to normalise, and neurotransmitter pathway recovery lags behind biochemical restoration. Starting the day you quit means you're navigating peak withdrawal severity (days 3–7) before NAD+ levels have meaningfully improved. Pair supplementation with behavioural support and consider combining with FDA-approved cessation aids rather than relying on NAD+ alone.

What If I've Tried Varenicline or Bupropion and They Didn't Work?

NAD+ supplementation addresses a different mechanism than varenicline (partial nAChR agonist) or bupropion (dopamine/norepinephrine reuptake inhibitor), making it a plausible adjunct for individuals who didn't respond to first-line therapies. However, 'didn't work' often reflects issues beyond pharmacology. Insufficient behavioural support, environmental triggers, or co-occurring mental health conditions that require integrated treatment. NAD+ won't override those factors. If previous attempts failed due to intolerable side effects rather than lack of efficacy, NAD+ precursors have a favourable safety profile and may be worth exploring under medical supervision.

What If I Want to Use IV NAD+ Infusions Instead of Oral Supplementation?

IV NAD+ delivers immediate tissue saturation (500–1,000mg per session reaches peak plasma concentration within 30–60 minutes), but the elevation is transient unless paired with oral maintenance dosing. Clinics offering NAD+ infusion protocols for addiction typically recommend 5–10 sessions over 10–14 days, followed by oral NR or NMN to sustain levels. The practical barriers are cost (sessions range from 200–500 USD each) and clinic access. If those aren't constraints, IV loading followed by oral maintenance is the most aggressive repletion strategy. Though clinical outcome data supporting this protocol specifically for smoking cessation remains limited.

The Unflinching Truth About NAD+ and Nicotine Addiction

Here's the honest answer: NAD+ supplementation will not make quitting smoking easy. It won't eliminate cravings, it won't override behavioural conditioning, and it won't compensate for lack of motivation or environmental support. The mechanism is real. Chronic nicotine use does deplete NAD+, and that depletion does impair dopamine synthesis during withdrawal. But correcting one biochemical deficit doesn't reverse a decade of receptor downregulation, synaptic remodelling, and learned associations between smoking and stress relief.

The clinical evidence for NAD+ as a cessation tool is weak. One uncontrolled pilot study and retrospective case series don't establish efficacy. They establish plausibility. Animal data is encouraging but rodent self-administration models don't account for the psychological complexity of human addiction. The supplement industry markets NAD+ infusions as breakthrough addiction therapy, but the truth is that varenicline, bupropion, and combination NRT consistently outperform NAD+ in head-to-head comparisons where such data exists.

That doesn't mean NAD+ is useless. It means it's a mechanistic adjunct. Not a standalone solution. If you're planning a quit attempt, prioritise proven interventions first: behavioural counselling, FDA-approved pharmacotherapy, and environmental restructuring. Add NAD+ precursors as a supporting strategy if you want to optimise dopamine pathway recovery during the first 30 days. But don't expect it to do the heavy lifting.

The research-grade peptides we supply at Real Peptides are designed for serious biological investigation. Not consumer self-experimentation. NAD+ precursors like NR and NMN belong in controlled research settings where dosing, purity, and outcome measures are rigorously tracked. If you're exploring NAD+ for personal cessation support, work with a prescribing physician who understands addiction medicine. Not a wellness clinic selling infusion packages without follow-up or outcome tracking.

If NAD+ supplementation becomes part of evidence-based cessation protocols in the next five years, it will be because researchers conducted the Phase III trials that don't exist yet. Until then, treat it as experimental. Promising, mechanistically sound, but unproven at the clinical standard required to displace existing therapies.

The information in this article is for educational purposes. NAD+ dosing, timing, and integration with cessation therapies should be decided in consultation with a licensed physician familiar with addiction pharmacology.

References

Peer-reviewed sources on NAD+ indexed in PubMed, listed for research context. Real Peptides supplies NAD+ for laboratory research use only.

  1. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing research reviews, 2026. PMID 41655607. doi:10.1016/j.arr.2026.103057
  2. NAD(+) restores proteostasis through splicing-dependent autophagy. Autophagy, 2026. PMID 41313318. doi:10.1080/15548627.2025.2596679
  3. Endothelial NAD(+) depletion drives vascular senescence and neuroinflammation via mtDNA-cGAS/STING-CD38 signaling in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. PMID 42033099. doi:10.1002/alz.71423
  4. NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations. JCI insight, 2026. PMID 41574612. doi:10.1172/jci.insight.181812
  5. NAD(+) depletion drives age-related monocyte hyperinflammation after stroke and is reversed by nicotinamide riboside. Journal of neuroinflammation, 2025. PMID 41299539. doi:10.1186/s12974-025-03638-6
  6. Lactate dehydrogenase A-coupled NAD(+) regeneration is critical for acute myeloid leukemia cell survival. Cancer & metabolism, 2025. PMID 40390151. doi:10.1186/s40170-025-00392-4
  7. FOXO1-NMNAT3 axis dysregulation promotes doxorubicin cardiotoxicity: NAD(+) replenishment as a redox-targeted antioxidant therapy. Redox report : communications in free radical research, 2025. PMID 41021886. doi:10.1080/13510002.2025.2565033
  8. NAD+ prevents chronic kidney disease by activating renal tubular metabolism. JCI insight, 2025. PMID 40059824. doi:10.1172/jci.insight.181443

Questions

NAD+ serves as a cofactor in the synthesis of dopamine, serotonin, and norepinephrine — neurotransmitters that nicotine artificially elevates and that withdrawal suppresses. Chronic smoking depletes cellular NAD+ by 28–40%, impairing the brain’s ability to produce these neurotransmitters naturally during cessation. Supplementation theoretically restores baseline production capacity, reducing the severity of withdrawal-driven cravings. However, human clinical trials have not yet demonstrated this effect in controlled settings — the mechanism is plausible based on animal data, but clinical efficacy remains unproven.
No. As of 2026, no Phase III randomised controlled trial has tested NAD+ supplementation as a primary cessation intervention, and existing evidence does not support it as a replacement for varenicline, bupropion, or nicotine replacement therapy. FDA-approved medications demonstrate 2–3× higher biochemically verified abstinence rates in head-to-head trials. NAD+ may serve as an adjunct to support neurotransmitter pathway recovery during withdrawal, but it cannot replace therapies with established clinical efficacy.
Oral NAD+ has less than 5% bioavailability because the molecule is too large to cross intestinal membranes intact and is degraded by gut enzymes before absorption. NAD+ precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are smaller molecules that are absorbed intact and converted to NAD+ inside cells. NR achieves 40–60% bioavailability, and NMN achieves 30–50%. For smoking cessation research, oral precursors are the practical choice — direct NAD+ supplementation delivers minimal tissue elevation.
Tissue NAD+ repletion takes 7–14 days of sustained supplementation at therapeutic doses (300–1,000mg daily NR or NMN), and neurotransmitter pathway recovery lags behind NAD+ normalisation by another 10–21 days. This means symptom relief is not immediate — starting supplementation the day you quit smoking means navigating peak withdrawal severity (days 3–7) before NAD+ levels have meaningfully improved. For best results, begin supplementation at least one week before your planned quit date.
NAD+ precursors (NR, NMN) have a favourable safety profile in human trials at doses up to 1,000mg daily, with mild gastrointestinal discomfort reported in fewer than 10% of participants. The primary risk is not physiological but strategic: relying on NAD+ as a sole cessation tool delays or replaces evidence-based therapies with proven efficacy. Patients who use NAD+ instead of varenicline, bupropion, or behavioural counselling may experience lower abstinence rates and higher relapse probability. NAD+ is best used as an adjunct, not a replacement.
No. NAD+ supplementation and IV infusion protocols are not FDA-approved for smoking cessation and are therefore not covered by health insurance plans. Patients pay out-of-pocket, with oral NR or NMN supplements costing 40–80 USD per month and IV NAD+ infusion sessions ranging from 200–500 USD each. FDA-approved cessation medications (varenicline, bupropion, NRT) are typically covered under prescription drug plans, making them far more cost-accessible.
Nicotine-induced NAD+ depletion (28–40% reduction in chronic smokers) is comparable to depletion observed in chronic alcohol use (35–50% reduction) but less severe than methamphetamine or opioid use disorders, which can reduce NAD+ by 50–70% in dopaminergic brain regions. The shared mechanism is excessive oxidative stress and mitochondrial dysfunction across all addictive substances. NAD+ restoration protocols are being explored across multiple addiction types, though clinical evidence is strongest for alcohol use disorder, where IV NAD+ has shown some efficacy in reducing acute withdrawal severity.
Yes — there is no known pharmacological interaction between NAD+ precursors and nicotine replacement products (gum, patches, lozenges). NRT delivers controlled nicotine doses to reduce withdrawal severity while you address behavioural triggers, and NAD+ supplementation theoretically supports dopamine pathway recovery independently. Combining the two is mechanistically sound, though no clinical trial has tested this specific combination. Consult your prescribing physician before starting any adjunctive therapy alongside FDA-approved cessation medications.
Mitochondria in dopaminergic neurons are primary targets of oxidative damage during chronic nicotine exposure. Nicotine increases mitochondrial calcium influx and reactive oxygen species production, impairing ATP synthesis and triggering compensatory NAD+ consumption. During withdrawal, impaired mitochondrial function reduces baseline dopamine output, contributing to anhedonia and fatigue. NAD+ supports mitochondrial biogenesis and oxidative stress response via sirtuin activation (particularly SIRT1 and SIRT3), which may partially restore energy metabolism in affected neurons. This is the biochemical rationale for NAD+ in cessation support, though clinical translation remains under investigation.
NAD+ supplementation lacks patent protection because NAD+ and its precursors (NR, NMN) are naturally occurring compounds, making them unattractive to pharmaceutical companies that fund Phase III trials. Without industry sponsorship, academic researchers face funding constraints that limit trial scale. The existing small pilot studies and case series are sufficient to establish biological plausibility but insufficient to meet FDA standards for therapeutic approval. Until a well-funded institution or government agency sponsors a randomised controlled trial with 500+ participants and biochemically verified outcomes, NAD+ will remain an experimental adjunct rather than a guideline-endorsed therapy.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now